You are here: Industry Insights > SEC

News List

Esperion Announces Proposed Public Offering FirstWordPharma
December 03, 2021
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) ("Esperion" or the "Company"), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock ...
NEWS SEC-MS: a “powerful tool” for ADC analysis, find researchers EuropeanPharmaceuticalReview
October 28, 2021
In a new study, scientists demonstrated that size exclusion chromatography (SEC) could be successfully combined with mass spectrometry (MS) to characterise antibody-drug conjugates (ADCs) on the intact molecular level.
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program firstwordpharma
August 17, 2021
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission ("SEC") to renew its previously established ATM facility under which it may offer and sell additional shares.
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares firstwordpharma
August 17, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced closing of its previously announced underwritten public offering of 7,590,000 shares of its common stock at a public offering price of $19.00 per share
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharm firstwordpharma
August 16, 2021
Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission ("SEC") on August 10
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules firstwordpharma
August 12, 2021
EyeGate Pharmaceuticals, Inc. today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share.
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock firstwordpharma
August 11, 2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares are being offered by Fulcrum.
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination firstwordpharma
August 05, 2021
Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021.
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Avidity Biosciences Announces Proposed Public Offering of Common Stock firstwordpharma
August 03, 2021
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering.

Previous page 1 2 3 4 5 Next page